Today: 13 June 2026
Bank of America stock drops as Treasury yields dip in thin year-end trade
29 December 2025
1 min read

Bank of America stock drops as Treasury yields dip in thin year-end trade

NEW YORK, December 29, 2025, 11:58 ET — Regular session

  • Bank of America shares fell about 1.3% as big U.S. bank stocks eased in holiday-thinned trading.
  • The 10-year Treasury yield slipped to 4.12%, a move traders watch closely for its impact on bank lending margins.
  • Investors are looking ahead to Fed minutes, weekly jobless claims and Bank of America’s Jan. 14 quarterly results.

Bank of America Corp (BAC) shares fell about 1.3% on Monday to $55.43 in late morning trading, as investors trimmed exposure to big U.S. lenders in year-end trade.

The move matters because bank profits are closely tied to interest-rate expectations. A flatter yield curve — when long-term rates fall relative to short-term rates — can squeeze the spread banks earn on lending.

With U.S. markets closed on Thursday for New Year’s Day and few major corporate catalysts on the calendar, traders have leaned on rate moves and macro signals to set positions.

Bank of America traded between $55.40 and $56.32 on the session, after opening at $56.03, market data showed.

Peers also slipped. JPMorgan Chase fell about 1%, Citigroup lost about 1.6% and Wells Fargo eased about 0.8%.

Exchange-traded funds tracking the group were lower, with the SPDR S&P Bank ETF down about 0.9% and the Financial Select Sector SPDR ETF off about 0.5%.

The 10-year U.S. Treasury yield, which influences interest rates on many consumer and business loans, slipped to 4.12% from just under 4.14% at Friday’s close, Investopedia reported.

“Bond market’s current stability relied on a ‘tenuous balance’,” Meghan Swiber, a senior U.S. rates strategist at BofA, told Reuters, pointing to subdued inflation expectations and the Treasury’s heavier reliance on shorter-maturity issuance. Reuters

Separately, CEO Brian Moynihan said on CBS’s “Face the Nation” that tariffs were settling around roughly 15% for many countries, according to Business Insider, comments that investors weigh for what they imply about business confidence and borrowing. Business Insider

On the data front, pending U.S. home sales rose 3.3% in November, beating economists’ expectations, the National Association of Realtors said, a sign of improving housing demand as mortgage rates ease.

Broader U.S. stocks were lower, led by a pullback in heavyweight technology names, after recent gains pushed the S&P 500 to record highs, Reuters reported. Some investors had been looking for a “Santa Claus rally,” a seasonal tendency for stocks to rise at the end of December and early January. Reuters

Next on the calendar, investors are watching minutes from the Federal Reserve’s last meeting and weekly jobless claims in an otherwise light week for U.S. data, Reuters said.

For Bank of America, the next major catalyst is its fourth-quarter earnings report on January 14, the bank’s investor relations site shows. Traders will be watching management’s read on net interest income — the difference between what a bank earns on loans and pays on deposits — along with trading revenue and credit quality heading into 2026.

Stock Market Today

  • Telix Pharmaceuticals Phase 3 ProstACT Safety Data Boosts Investment Outlook
    June 12, 2026, 8:05 PM EDT. Telix Pharmaceuticals (ASX:TLX) announced early Phase 3 ProstACT trial data for TLX591-Tx in metastatic castration-resistant prostate cancer, demonstrating an acceptable safety and tolerability profile with no new safety concerns. The lower kidney and salivary gland exposure compared to existing therapies could signal a differentiated advantage. This supports Telix's shift from diagnostics to higher-value therapeutics but hinges on upcoming pivotal trial results. A new U.S. collaboration with United Imaging aims to enhance theranostics workflow and commercial scale. Despite promising clinical progress, risks include regulatory scrutiny following an SEC subpoena over prostate cancer disclosures. Analysts forecast 22.7% annual revenue growth to A$1.2 billion by 2029, with an 85% upside to Telix's current price. Market watchers weigh potential regulatory and execution challenges against long-term growth prospects in theranostics.

Latest articles

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

SGH Limited Holds Back as ASX 200 Pushes Higher Before FY26 Results

13 June 2026
SGH closed at A$41.51, up 0.70% but underperformed the S&P/ASX 200’s 1.98% surge, as investors weighed solid cash flow and Boral margin gains against a high 36.03 P/E, mixed demand, and M&A risk; the next key catalyst is FY26 results on August 11, with analysts’ average target at A$47.64, 14.76% above Friday’s close.
NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

NCR Voyix Rallies 10% After Investors Shift on Turnaround Bets

13 June 2026
NCR Voyix soared 10.25% to $7.85, far outpacing the market, as investors focus on the company’s 2026 cash-flow and earnings targets; the next key catalyst is the Q2 2026 earnings update, with stock valuation appearing low if management delivers on margin and cash-flow goals, but risks remain with declining reported revenue and high debt.
Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386
Previous Story

Tesla stock slips as supplier guts $2.9 bln battery deal to $7,386

MongoDB stock slides as “MongoBleed” exploitation warning puts database security in focus
Next Story

MongoDB stock slides as “MongoBleed” exploitation warning puts database security in focus

Go toTop